The effect of a multi-strain probiotic on the resistance toward Escherichia coli challenge in a randomized, placebo-controlled, double-blind intervention study

European Journal of Clinical Nutrition

Volumn 69, Issue 3, 2015, Pages 385-391

  Ten Bruggencate, S J M ^a   Girard, S A ^b   Floris Vollenbroek, E G M ^a   Bhardwaj, R ^b   Tompkins, T A ^b  

^a NIZO FOOD RESEARCH   (Netherlands)

^b LALLEMAND SAS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; IMMUNOGLOBULIN G; PROBIOTIC AGENT; SECRETORY IMMUNOGLOBULIN;

ADULT; ARTICLE; BACTERIAL CLEARANCE; BIFIDOBACTERIUM LONGUM; BRISTOL STOOL SCORE; COLONY FORMING UNIT; CONTROLLED STUDY; DAILY RECORD QUESTIONNAIRE; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; ENTEROTOXIGENIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FECES ANALYSIS; FECES COMPOSITION; FEMALE; GASTROINTESTINAL INFECTION; HUMAN; INFECTION RESISTANCE; LACTOBACILLUS HELVETICUS; LACTOBACILLUS RHAMNOSUS; MALE; NONHUMAN; PARALLEL DESIGN; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SACCHAROMYCES CEREVISIAE; SCORING SYSTEM; BIFIDOBACTERIUM; DEFECATION; DIARRHEA; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FECES; INTESTINE; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; MICROBIOLOGY; YOUNG ADULT;

BIFIDOBACTERIUM LONGUM; ESCHERICHIA COLI; LACTOBACILLUS HELVETICUS; LACTOBACILLUS RHAMNOSUS; SACCHAROMYCES CEREVISIAE;

ADULT; BIFIDOBACTERIUM; DEFECATION; DIARRHEA; DOUBLE-BLIND METHOD; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FECES; HUMANS; INTESTINES; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS HELVETICUS; LACTOBACILLUS RHAMNOSUS; MALE; PROBIOTICS; YOUNG ADULT;

EID: 84924617491     PISSN: 09543007     EISSN: 14765640     Source Type: Journal    
DOI: 10.1038/ejcn.2014.238     Document Type: Article

References (28)

1. Field V, Gautret P, Schlagenhauf P, Burchard GD, Caumes E, Jensenius M et al. Travel and migration associated infectious diseases morbidity in Europe, 2008. BMC Infect Dis 2010; 10: 330.
2. McFarland LV. Diarrhoea associated with antibiotic use. BMJ 2007; 335: 54-55.
3. Schjorring S, Krogfelt KA. Assessment of bacterial antibiotic resistance transfer in the gut. Int J Microbiol 2011; 2011: 312956.
4. Agustina R, Kok FJ, van de Rest O, Fahmida U, Firmansyah A, Lukito W et al. Randomized trial of probiotics and calcium on diarrhea and respiratory tract infections in Indonesian children. Pediatrics 2012; 129: e1155-e1164.
5. McFarland LV. Meta-analysis of probiotics for the prevention of traveler's diarrhea. Travel Med Infect Dis 2007; 5: 97-105.
6. Sazawal S, Hiremath G, Dhingra U, Malik P, Deb S, Black RE. Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. Lancet Infect Dis 2006; 6: 374-382.
7. McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 2010; 16 : 2202-2222.
8. Szajewska H, Skorka A, Dylag M. Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children. Aliment Pharmacol Ther 2007; 25: 257-264.
9. Htwe K, Yee KS, Tin M, Vandenplas Y. Effect of Saccharomyces boulardii in the treatment of acute watery diarrhea in Myanmar children: a randomized controlled study. Am J Trop Med Hyg 2008; 78: 214-216.
10. Kurugol Z, Koturoglu G. Effects of Saccharomyces boulardii in children with acute diarrhoea. Acta Paediatr 2005; 94: 44-47.
11. Villarruel G, Rubio DM, Lopez F, Cintioni J, Gurevech R, Romero G et al. Saccharomyces boulardii in acute childhood diarrhoea: a randomized, placebo-controlled study. Acta Paediatr 2007; 96: 538-541.
12. Kollaritsch H, Holst H, Grobara P, Wiedermann G. [Prevention of traveler's diarrhea with Saccharomyces boulardii. Results of a placebo controlled double-blind study]. Fortschr Med 1993; 111 : 152-156.
13. Bisson JF, Hidalgo S, Rozan P, Messaoudi M. Preventive effects of different probiotic formulations on travelers' diarrhea model in wistar rats: preventive effects of probiotics on TD. Dig Dis Sci 2010; 55: 911-919.
14. Bovee-Oudenhoven IM, Lettink-Wissink ML, Van Doesburg W, Witteman BJ, Van Der Meer R. Diarrhea caused by enterotoxigenic Escherichia coli infection of humans is inhibited by dietary calcium. Gastroenterology 2003; 125: 469-476.
15. Ten Bruggencate SJ, Bovee-Oudenhoven IM, Lettink-Wissink ML, Katan MB, van der Meer R. Dietary fructooligosaccharides affect intestinal barrier function in healthy men. J Nutr 2006; 136: 70-74.
16. Klein SM, Elmer GW, McFarland LV, Surawicz CM, Levy RH. Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii, in healthy human volunteers. Pharm Res 1993; 10: 1615-1619.
17. Levine MM, Ferreccio C, Prado V, Cayazzo M, Abrego P, Martinez J et al. Epidemiologic studies of Escherichia coli diarrheal infections in a low socioeconomic level peri-urban community in Santiago, Chile. Am J Epidemiol 1993; 138: 849-869.
18. Isidean SD, Riddle MS, Savarino SJ, Porter CK. A systematic review of ETEC epidemiology focusing on colonization factor and toxin expression. Vaccine 2011; 29: 6167-6178.
19. Heaton KW, Ghosh S, Braddon FE. How bad are the symptoms and bowel dysfunction of patients with the irritable bowel syndrome? A prospective, controlled study with emphasis on stool form. Gut 1991; 32: 73-79.
20. Porter CK, Riddle MS, Tribble DR, Louis Bougeois A, McKenzie R, Isidean SD et al. A systematic review of experimental infections with enterotoxigenic Escherichia coli (ETEC). Vaccine 2011; 29: 5869-5885.
21. Kollaritsch H, Paulke-Korinek M, Wiedermann U. Traveler's Diarrhea. Infect Dis Clin North Am 2012; 26: 691-706.
22. Rendi-Wagner P, Kollaritsch H. Drug prophylaxis for travelers' diarrhea. Clin Infect Dis 2002; 34: 628-633.
23. Croxen MA, Law RJ, Scholz R, Keeney KM, Wlodarska M, Finlay BB. Recent Advances in Understanding Enteric Pathogenic Escherichia coli. Clin Microbiol Rev 2013; 26: 822-880
24. Ouwehand AC, Ten Bruggencate SJ, Schonewille AJ, Alhoniemi E, Forssten SD, Bovee-Oudenhoven IM. Lactobacillus acidophilus supplementation in human subjects and their resistance to enterotoxigenic Escherichia coli infection. Br J Nutr 20131-9.
25. Corr SC, Hill C, Gahan CG. Understanding the mechanisms by which probiotics inhibit gastrointestinal pathogens. Adv Food Nutr Res 2009; 56: 1-15.
26. Castagliuolo I, Riegler MF, Valenick L, LaMont JT, Pothoulakis C. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 1999; 67: 302-307.
27. Paton AW, Jennings MP, Morona R, Wang H, Focareta A, Roddam LF et al. Recombinant probiotics for treatment and prevention of enterotoxigenic Escherichia coli diarrhea. Gastroenterology 2005; 128: 1219-1228.
28. Rund SA, Rohde H, Sonnenborn U, Oelschlaeger TA. Antagonistic effects of probiotic Escherichia coli Nissle 1917 on EHEC strains of serotype O104:H4 and O157:H7. Int J Med Microbiol 2013; 303: 1-8.